Incidence of cardiovascular events and vascular interventions in patients with type 2 diabetes

被引:28
|
作者
Engelen, Suzanne E. [1 ]
van der Graaf, Yolanda [5 ]
Stam-Slob, Manon C. [1 ]
Grobbee, Diederick E. [5 ]
Cramer, Maarten J. [2 ]
Kappelle, L. Jaap [3 ]
de Borst, Gert J. [4 ]
Visseren, Frank L. J. [1 ]
Westerink, Jan [1 ]
机构
[1] Univ Med Ctr Utrecht, Dept Vasc Med, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands
[2] Univ Med Ctr Utrecht, Dept Cardiol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands
[3] Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Dept Neurol, Univ Weg 100, NL-3584 CG Utrecht, Netherlands
[4] Univ Med Ctr Utrecht, Dept Vasc Surg, Utrecht, Netherlands
[5] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Univ Weg 100, NL-3584 CG Utrecht, Netherlands
关键词
Type; 2; diabetes; Cardiovascular disease; Interventions; PERIPHERAL ARTERIAL-DISEASE; SIROLIMUS-ELUTING STENTS; OUTCOMES; THROMBOSIS; MELLITUS; RISK; MORTALITY;
D O I
10.1016/j.ijcard.2017.07.081
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Diabetes mellitus is associated with an increased risk for cardiovascular morbidity and mortality. The vascular burden in terms of incidence of cardiovascular events (CVE) and vascular interventions is however poorly quantified. In this study we evaluated the incidence rates of CVE and vascular interventions in patients with type 2 diabetes (T2DM) with and without cardiovascular disease (CVD) in comparison to patients without type 2 diabetes. Research design and methods: In a cohort of 9.808 high-risk patients with and without cardiovascular disease and type 2 diabetes originated from the ongoing, single-center prospective SMART (Second Manifestations of ARTerial disease) cohort, the number and incidence rates of CVE and interventions were calculated. The incidence rates were adjusted for confounders using Poisson regression models. CVE were defined as vascular death, stroke and myocardial infarction (MI). Interventions were defined as percutaneous coronary intervention, coronary artery bypass grafting, percutaneous transluminal angioplasty or stenting of the peripheral arteries and amputation. Results: Patients with T2DM and CVD had a 4-fold higher incidence rate of CVE and a 8-fold higher incidence rate of vascular interventions compared to high-risk patients without T2DM and CVD after adjusting for confounders. The incidence rate for the composite of non-fatal MI, non-fatal stroke and vascular death was 5.8 per 1000 person-years in patients without T2DM or CVD at baseline, 15.2 per 1000 person-years in patients with T2DM but without CVD at baseline, 26.0 per 1000 person-years in patients without T2DM but with CVD and 40.7 per 1000 person-years in patients with both T2DM and CVD at baseline. A similar increasing incidence rate was seen for all vascular interventions from patients without T2DM or CVD to patients with both T2DM and CVD. Conclusions: Patients with type 2 diabetes or CVD are subject to an increased incidence of cardiovascular events and interventions compared to high-risk patients without type 2 diabetes or vascular disease. Patients with type 2 diabetes and CVD have the highest incidence of new cardiovascular diseases and vascular interventions when compared to patients without type 2 diabetes and CVD. These results underline the need for optimal risk factor treatment as well as the need for new prevention and treatment strategies in this very high risk population. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:301 / 307
页数:7
相关论文
共 50 条
  • [21] Increased risk of cardiovascular events among type 2 diabetes patients with dyslipidemia
    Blonde, Lawrence
    Fox, Kathleen M.
    Ohsfeldt, Robert L.
    Parikh, Shamik
    Grandy, Susan
    CIRCULATION, 2007, 115 (08) : E230 - E230
  • [22] New evidence on the prevention of cardiovascular events in hypertensive patients with type 2 diabetes
    Pahor, M
    Psaty, BM
    Furberg, CD
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1998, 32 : S18 - S23
  • [23] What is the effect of fenofibrate on cardiovascular disease events in patients with type 2 diabetes?
    Mazzone, T.
    NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2006, 2 (07): : 366 - 367
  • [24] Characterization and cholesterol management in patients with cardiovascular events and/or type 2 diabetes in the Netherlands
    Heintjes, Edith
    Kuiper, Josephina
    Lucius, Bianca
    Penning-van Beest, Fernie
    Kutikova, Lucie
    Liem, Anho
    Herings, Ron
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (01) : 91 - 100
  • [25] Risk factor control and cardiovascular events in patients with type 2 diabetes mellitus
    Song, Do Kyeong
    Hong, Young Sun
    Sung, Yeon-Ah
    Lee, Hyejin
    PLOS ONE, 2024, 19 (02):
  • [26] Relationship of thyroid hormone levels and cardiovascular events in patients with type 2 diabetes
    Moura Neto, A.
    Parisi, M. C. R.
    Tambascia, M. A.
    Pavin, E. J.
    Alegre, S. M.
    Zantut-Wittmann, D. E.
    ENDOCRINE, 2014, 45 (01) : 84 - 91
  • [27] Adiponectin and atherosclerosis related cardiovascular events in type 2 diabetes dialysis patients
    Kacso, I. M.
    Potra, A. R.
    Bondor, C. I.
    Moldovan, D.
    Rusu, C.
    Patiu, I. M.
    Racasan, S.
    Orasan, R.
    Vladutiu, D.
    Spanu, C.
    Rusu, A.
    Nita, C.
    Moldovan, R.
    Ghigolea, B.
    Kacso, G.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2015, 45 : 90 - 90
  • [28] LDL-CHOLESTEROL AND CARDIOVASCULAR EVENTS IN PATIENTS WITH DIABETES MELLITUS TYPE 2
    Tudor, C.
    Iana, A.
    Jeberean, R. A.
    Petrus, A.
    Buzas, R.
    ATHEROSCLEROSIS SUPPLEMENTS, 2010, 11 (02) : 33 - 34
  • [29] What is the effect of fenofibrate on cardiovascular disease events in patients with type 2 diabetes?
    Theodore Mazzone
    Nature Clinical Practice Endocrinology & Metabolism, 2006, 2 : 366 - 367
  • [30] Relationship of thyroid hormone levels and cardiovascular events in patients with type 2 diabetes
    A. Moura Neto
    M. C. R. Parisi
    M. A. Tambascia
    E. J. Pavin
    S. M. Alegre
    D. E. Zantut-Wittmann
    Endocrine, 2014, 45 : 84 - 91